0
LìfeSciencesHealth, a shining future?
Dr. Roland Lageveen
CEO IQ Corporation
Biotechnology in the Netherlands
The Dutch life sciences and health innovation
cluster (LSH) builds upon a strong knowledge base
Strong national cluster:
F...
• Impact publications number 4
• Publication productivity number 2
• Patent productivity number 1
…with excellent output l...
Source: OECD, Biotechnology Statistics 2009
…and a good biotechnology patent
productivity too…
patent productivity number 1
Health-related life sciences: an important sector in
the Dutch economy
Drugs
– 430 companies; EUR 12 bn revenues; 37,000 F...
5 of the top 10 European biotech deals are with Dutch
companies, with a total value exceeding USD 2 billion
However….
…but a low performance on innovation &
entrepreneurship and applications
1 Finland
2 Finland
3 Finland Finland
4 Finland U...
Aggregate uptake of 13 innovative first-line products
(launched between January 2004 - June 2008)
0,00
0,04
0,08
0,12
0,16...
Nyenrode Biotech Outlook: The performance
of Dutch cluster is low but improving
Investments in PPPs are huge, but will
decline
Source: PPP websites; Senternovem; Ministery of Economic
Affairs
PPP progra...
The government recognizes life sciences as
‘topgebied’, next to food & flowers and chemicals
The government recognizes life sciences but their
budgets ......
• Wbso higher
• Tax lower
But:
• No specific programs
• N...
The international environment
is changing…..
15
The big Pharma challenge: R&D expenditure
goes up, output in new medicines goes down
0
40
80
120
1996
1997
1998
1999
20...
November 2007:
Schering-Plough buys Organon for USD 14.4
bn
November 2009:
Schering-Plough and Merck merge,
Merck (MSD in ...
...with a major impact on the Netherlands
Organon Solvay Crucell
At the same time big Pharma tries to fill its pipelines
by increasing external R&D activities
Company Turnover R&D % of
tu...
The changing environment holds
opportunities for the
Netherlands….
Societal, technological and stakeholder trends holds
opportunities for the Netherlands
Dutch business environment and gove...
The Netherlands has a good start position to turn into
an international breeding ground for new businesses
Increasing dema...
How can we grab the
opportunities ?
A clear challenge for the Dutch sector: big and
small, clinical and pre-clinical, public and private,
branch organizations...
Generation Translation Delivery
BUILD BENEFITBUNDLE
…with a
technology
push…
…resting on
a strong
knowledge
base…
…deliver...
Invest on an annual basis with a stable budget for a
longer period instead of incidental impulse financing
130
263
248
200...
Improve the LSH climate
• Creating a SME friendly environment fostered by a
government with long term vision and a positiv...
Keep effective, successful instruments up and
running
For example: ‘Innovatiekrediet’
1 euro credit loan… generates 2 euro...
Stakeholders should team up to realize these goals
• The knowledge base: UMC’s and Universities
• The industry: small and ...
One voice one message ….
….. show our successes!
Dutch Masters in Life Sciences Health,
…..The Dutch Innovation
Biotechnology in the Netherlands
LSH a shining future?
Let’s team up to make it happen together
Dr. Roland Lageveen
CEO IQ...
Upcoming SlideShare
Loading in...5
×

4 nov 2010: Presentation Roland Lageveen on biotechnology in the NL.

838

Published on

Biofarmind celebrates its 12.5th anniversary. Roland Lageveen (IQ Corporations) talks about biotechnology in the Netherlands.

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
838
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
9
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide
  • Our approach is paying offIn 2008 a strong growth in attracted venture capital against all oddsIn the top 10 European biotech-Pharma partnerships, 5 involve Dutch SME’sAn example: Prosensaand its partnership with GSK - Development and commercialization of RNA based therapeutics for Duchenne Muscular Dystrophy (DMD)- Deal value of upfront and milestone payments USD 655 million
  • Transcript of "4 nov 2010: Presentation Roland Lageveen on biotechnology in the NL. "

    1. 1. LìfeSciencesHealth, a shining future? Dr. Roland Lageveen CEO IQ Corporation Biotechnology in the Netherlands
    2. 2. The Dutch life sciences and health innovation cluster (LSH) builds upon a strong knowledge base Strong national cluster: First rate academia, hundreds of SME’s, multinational med- & biotech and Pharma, all within a 120 mile radius Focal points around: - Amsterdam/Leiden/Rotterdam/Utrecht - Groningen - Wageningen/Nijmegen - Eindhoven/Maastricht World class: – Two Dutch clusters are in the global Top 40 and the European Top 15 for biotech patent applications. 120 mile radius Excellent biobanks and ‘real life’ data infrastructure Global players & very high concentration of SMEs
    3. 3. • Impact publications number 4 • Publication productivity number 2 • Patent productivity number 1 …with excellent output levels 2,5% of world science output www.worldmapper.org
    4. 4. Source: OECD, Biotechnology Statistics 2009 …and a good biotechnology patent productivity too… patent productivity number 1
    5. 5. Health-related life sciences: an important sector in the Dutch economy Drugs – 430 companies; EUR 12 bn revenues; 37,000 FTE Diagnostics – 390 companies; EUR 2.7 bn revenues; 12,000 FTE Biomedical Engineering and Devices – 75 companies; EUR 0.4 bn revenues; 2,200 employees Other – 40 companies,  EUR 0.8 bn revenues Health-related life sciences: 935 companies – 150 highly innovative; EUR 15.9 bn output (3% of GDP); 54,600 FTE Source: EIM study for EZ [2006], Voorstel LSG [2006]
    6. 6. 5 of the top 10 European biotech deals are with Dutch companies, with a total value exceeding USD 2 billion
    7. 7. However….
    8. 8. …but a low performance on innovation & entrepreneurship and applications 1 Finland 2 Finland 3 Finland Finland 4 Finland United Kingdom 5 6 7 United Kingdom 8 The Netherlands 9 United Kingdom 10 The Netherlands The Netherlands 11 12 13 United Kingdom 14 15 United Kingdom 16 17 18 The Netherlands The Netherlands Innovation drivers Knowledge creation Innovation & Entrepreneurship Applications Intellectual Property Source: European Innovation Scoreboard 2006
    9. 9. Aggregate uptake of 13 innovative first-line products (launched between January 2004 - June 2008) 0,00 0,04 0,08 0,12 0,16 0 1 2 3 4 5 6 7 8 9 10 11 12 Months after launch Unitvolumepercapita Belgium Denmark France Germany Netherlands Switzerland UK After UK, the Netherlands has 2nd lowest market uptake of innovative medicines
    10. 10. Nyenrode Biotech Outlook: The performance of Dutch cluster is low but improving
    11. 11. Investments in PPPs are huge, but will decline Source: PPP websites; Senternovem; Ministery of Economic Affairs PPP programs – duration and total investment Investment in time [EUR m] (committed 2003-2007) 1) Includes also non-health related investments 11100908 150706 141312 NGI 5001) TI Pharma 240 CTMM 400 90 dpte SCDD 18 Cyttron 18 Parelsnoer 67 LifeLines 5 Program [EUR m] Neuro-BSIK 7BioMaDe 23TREND 28Arthrosite 24Braingain BMM 26 Mol Im Heart 20 24NIMIC 25TERM 50 248 263257 ?? Committed FES 2009 2007 2008 2009 2010 2011 2012 2013 2014 2015 Taken to the next level… …momentum lost? …or… 182 42 34 11 0 0
    12. 12. The government recognizes life sciences as ‘topgebied’, next to food & flowers and chemicals
    13. 13. The government recognizes life sciences but their budgets ...... • Wbso higher • Tax lower But: • No specific programs • No FES funding • No vision
    14. 14. The international environment is changing…..
    15. 15. 15 The big Pharma challenge: R&D expenditure goes up, output in new medicines goes down 0 40 80 120 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 0 20 40 60 Source: PhRMA, FDA R&D investments R&Dinvestment[USDbillion] FDA approved new medicines FDAapprovednewmedicines[#] R&D investments [USD billions] versus output [approved new medicines] Development of a new drug has become more complex: safety & efficacy are the two main issues Costs to develop one new drug have become approximately EUR 1 billion
    16. 16. November 2007: Schering-Plough buys Organon for USD 14.4 bn November 2009: Schering-Plough and Merck merge, Merck (MSD in Europe) pays USD 41.1 bn March 2009: Roche buys remaining 44% of shares in Genentech for USD 46.8 bn January 2009: Wyeth merges with Pfizer, Pfizer pays USD 68 bn September 2009: Abbott buys Solvay Pharmaceuticals from Solvay paying USD 6.6 bn Reducing costs and filling pipelines are two main drivers for consolidation in big Pharma Examples of mergers and acquisitions in big Pharma
    17. 17. ...with a major impact on the Netherlands Organon Solvay Crucell
    18. 18. At the same time big Pharma tries to fill its pipelines by increasing external R&D activities Company Turnover R&D % of turnover Highlights of R&D strategy GSK (2009) GBP 28.4 bn 4.1 bn 14% Increase the percentage of external R&D from 33% to 50% Merck (MSD, 2007) USD 26.8 bn 4.9 bn 18% Target to realize 25% of early pipeline via ‘External Basic Research program’ in the next 3-5 years AstraZeneca (2008) USD 31.6 bn 5.2 bn 16% Move from ‘research’ to ‘search’: RoI of dollars spent on external R&D is 3 times higher than internally spent Source: annual reports and websites GSK, Merck, and AstraZeneca, and Morgan Stanley report on AZ Examples from three major Pharma companies with highlights of their R&D strategy
    19. 19. The changing environment holds opportunities for the Netherlands….
    20. 20. Societal, technological and stakeholder trends holds opportunities for the Netherlands Dutch business environment and government innovation policy Societal trends1 15% 201 0 20% 202 0 24% 203 0 26% 204 0 % population >65 years in the Netherlands Technological trends Bio-artificial kidney Stakeholder trends3 4 2 Marketing/ sales Production company Technology provider Clinical research company • Ageing • Unhealthy lifestyle • Demand for high quality of life Increased burden on the healthcare system New technologies promise: • Early diagnosis • Targeted delivery of drugs • Personalized medicine • Specialization • Networks • Open innovation • Promising business environment • Life sciences anchored on short term in government innovation policy • Pitfall is lack of continuity in policy
    21. 21. The Netherlands has a good start position to turn into an international breeding ground for new businesses Increasing demand for innovations Increasing specialization Strong Dutch knowledge base Highly educated people Strong innovation infrastructure Growing industry Internationally competitive breeding ground for new business in life sciences and health + + + + = + OPPORTUNITY TO BECOME
    22. 22. How can we grab the opportunities ?
    23. 23. A clear challenge for the Dutch sector: big and small, clinical and pre-clinical, public and private, branch organizations now have to join forces
    24. 24. Generation Translation Delivery BUILD BENEFITBUNDLE …with a technology push… …resting on a strong knowledge base… …delivering continuously … …acting as a well oiled engine… …with a strong industry pull A healthy pipeline… Creating a healthy pipeline by building true partnerships
    25. 25. Invest on an annual basis with a stable budget for a longer period instead of incidental impulse financing 130 263 248 2007 2008 2009 2010 2011 2012 2013 2014 2015 Taken to the next level… …momentum lost? …or… 182 42 34 11 0 0 The sector should take responsibility for a long term strategy
    26. 26. Improve the LSH climate • Creating a SME friendly environment fostered by a government with long term vision and a positive LSH attitude • Remove regulation hurdles • Focus on value creation in the reimbursement evaluation procedure • Increase the availability of human resources • Improve entrepreneurial skills • Make EC’s “Innovation Union” work for us, in funding R&D and matching VC • Market the Netherlands internationally as one unique life sciences region
    27. 27. Keep effective, successful instruments up and running For example: ‘Innovatiekrediet’ 1 euro credit loan… generates 2 euro private investment 2009: 13 mln. + 26 mln. = 39 mln. +
    28. 28. Stakeholders should team up to realize these goals • The knowledge base: UMC’s and Universities • The industry: small and large • The financing world • The branch organizations • Patient organizations • Health care providers • Health insurers • ….
    29. 29. One voice one message …. ….. show our successes! Dutch Masters in Life Sciences Health, …..The Dutch Innovation
    30. 30. Biotechnology in the Netherlands LSH a shining future? Let’s team up to make it happen together Dr. Roland Lageveen CEO IQ Corporation
    1. A particular slide catching your eye?

      Clipping is a handy way to collect important slides you want to go back to later.

    ×